A comprehensive global market report on this high-growth sector
The POC cardiology diagnostics market was worth over US$2 billion in 2011 and rose by 9% compared with 2010. This was driven by a growing interest in the adoption of POC technologies by both healthcare providers and patients at home, as well as the introduction of new products that enable POC testing for more applications, enhance ease-of-use and improve on current products.
POC testing can offer clear benefits over laboratory testing. As it is conducted in the presence of or near the patient, results are obtained quickly, enabling healthcare providers to act swiftly to emergencies such as heart attack and provide a diagnosis while the patient is still in the healthcare facility, speeding treatment and reducing visits to the doctor. For patients, self-testing helps users control their condition, reducing the chance of complications and improving health, while lowering the time and cost of treating complications, and the need for patients to regularly see their doctor.
Clinical acceptance remains an obstacle
This is a key issue. Healthcare providers need evidence that POC diagnostics provide lab-quality results and benefits in terms of clinical-usefulness, convenience and cost in order to adopt them. Unsurprisingly, concerns have been raised by laboratory professionals about the decentralisation of hospital testing and by doctors about patient and consumer self-testing. In both cases, there is concern that the use of POC products by less skilled users may result in inaccurate diagnoses, leading to resistance to the changes needed for POC products to be widely implemented.
Overcoming these issues will be critical to the POC diagnostic sector if it is to realise its full potential – at present, adoption and usage rates vary widely, and there remains much untapped potential in the worldwide market.
Cardiology Point of Care Diagnostics Products, Players and Outlook to 2017
Published: September 2012 Price: US $ 1390
Innovation is making an impact
There is currently much innovation in the market. Products that enable multi-parameter diagnostics using technologies such as microfluidics are a major focus, as are products for personalised medicine. For example, the first POC DNA analysis system, Spartan Bioscience’s RX CYP2C19, has European approval to help identify patients with impaired metabolism to the popular anti-blood clotting medication, clopidogrel.
This new September 2012 report delivers a complete and insightful analysis
This new 130-page highly detailed report – Volume 1 of a 4-volume study of the whole IVD sector to be published this autumn/winter – provides executives with a complete understanding of the issues which are shaping the market and how they will affect its commercial development.
The POC cardiology diagnostics market was worth over US$2 billion in 2011 and rose by 9% compared with 2010. This was driven by a growing interest in the adoption of POC technologies by both healthcare providers and patients at home, as well as the introduction of new products that enable POC testing for more applications, enhance ease-of-use and improve on current products.
POC testing can offer clear benefits over laboratory testing. As it is conducted in the presence of or near the patient, results are obtained quickly, enabling healthcare providers to act swiftly to emergencies such as heart attack and provide a diagnosis while the patient is still in the healthcare facility, speeding treatment and reducing visits to the doctor. For patients, self-testing helps users control their condition, reducing the chance of complications and improving health, while lowering the time and cost of treating complications, and the need for patients to regularly see their doctor.
Clinical acceptance remains an obstacle
This is a key issue. Healthcare providers need evidence that POC diagnostics provide lab-quality results and benefits in terms of clinical-usefulness, convenience and cost in order to adopt them. Unsurprisingly, concerns have been raised by laboratory professionals about the decentralisation of hospital testing and by doctors about patient and consumer self-testing. In both cases, there is concern that the use of POC products by less skilled users may result in inaccurate diagnoses, leading to resistance to the changes needed for POC products to be widely implemented.
Overcoming these issues will be critical to the POC diagnostic sector if it is to realise its full potential – at present, adoption and usage rates vary widely, and there remains much untapped potential in the worldwide market.
Cardiology Point of Care Diagnostics Products, Players and Outlook to 2017
Published: September 2012 Price: US $ 1390
Innovation is making an impact
There is currently much innovation in the market. Products that enable multi-parameter diagnostics using technologies such as microfluidics are a major focus, as are products for personalised medicine. For example, the first POC DNA analysis system, Spartan Bioscience’s RX CYP2C19, has European approval to help identify patients with impaired metabolism to the popular anti-blood clotting medication, clopidogrel.
This new September 2012 report delivers a complete and insightful analysis
This new 130-page highly detailed report – Volume 1 of a 4-volume study of the whole IVD sector to be published this autumn/winter – provides executives with a complete understanding of the issues which are shaping the market and how they will affect its commercial development.
No comments:
Post a Comment